• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Here's My Biotechnology Shopping List

Biotechnology is always high risk but the right plays move unlike anything else.
By JAMES "REV SHARK" DEPORRE
Jul 29, 2020 | 02:02 PM EDT
Stocks quotes in this article: IBB, OCUL, PSNL, AUPH, FENC, MYOV, TRIL, MYOK, OTLK, AXSM, MEIP, KPTI

One of my favorite groups off the March lows has been biotechnology (IBB) . The sector bounced close to 60% with many individual names doing even better.  The IBB (iShares Nasdaq Biotechnology ETF) topped on 7/20 and is now testing its 50-day moving average.

There has been some broad pressure in the group today and yesterday, and I suspect that it may have something to do with increased talk about drug pricing controls. Many of these biotechnology names have promising drugs but if pricing is constrained it will have a major impact on valuation. There is a long way to go before there will be any actual legislation but the election in November will have an impact on this as well.

In the meanwhile, I'm seeing a number of stocks pulling back without any regard to their individual merits. Some of the names on my shopping list include: (OCUL) , (PSNL) , (AUPH) , (FENC) , (MYOV) , (TRIL) , (MYOK) , (OTLK) , (AXSM) , (MEIP) , (KPTI) , and several more.

Most of these charts are not particularly attractive at this point but I'll be looking for some support levels to form and will be interested in accumulating on upticks rather than further downticks.

Biotechnology is always high risk but the right plays move unlike anything else.

We are on hold now as we await the Fed. I expect to see some choppy action on the news.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, James "Rev Shark" DePorre was Long OCUL, PSNL, AUPH, FENC, MYOV, TRIL, MYOK, OTLK, AXSM, MEIP, KPTI.

TAGS: Drug Approvals | Investing | Markets | Stocks | Trading | Biotechnology | Pharmaceuticals

More from Investing

Bearish Bets: 3 Stocks You Should Think About Shorting This Week

Bob Lang
Jun 26, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

For Smith & Wesson, Load, Cock and Fire Another Round

Bret Jensen
Jun 26, 2022 7:30 AM EDT

Here's how to aim for this gunmaker once more with a covered-call play.

The 10 Personality Traits of Successful Traders and Investors

James "Rev Shark" DePorre
Jun 25, 2022 10:00 AM EDT

Superior market players share these characteristics in their emotional makeup.

Does the Big Bounce Mean More to Come? Let's See What Drove the Move

James "Rev Shark" DePorre
Jun 24, 2022 4:42 PM EDT

Much of the rally can be attributed to structural reasons, not fundamentals, technicals, or even macro ones.

MongoDB Is Poised for a Rally

Bruce Kamich
Jun 24, 2022 2:15 PM EDT

Here's our initial upside price target for MDB which provides a general purpose database platform.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login